In Depth 17 Jan 2023 Cell and gene therapies gain momentum in Basel Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the globe, and a growing number are choosing the Swiss city of Basel as their base. These companies are taking advantage of the talent pool, academic institutions and investors that the area has to offer, culturing […] January 17, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 11 Jan 2023 Drug repurposing emerges as viable option for rare disease treatment With few options available for the treatment of rare diseases, the practice of drug repurposing has gained traction as an effective strategy. With genome sequencing revealing new rare diseases, it is now known that at least 5% of the world population lives with a rare disease. Drug development must pick up the pace to keep […] January 11, 2023 - 7 minutesmins - By Sachin Rawat Share WhatsApp Twitter Linkedin Email
In Depth 10 Jan 2023 Innovative biomaterials are revolutionizing tissue regeneration Scientists are increasingly realizing the potential of biomaterials to help with many tasks. A key area biomaterials are being used in is tissue engineering and regeneration, something several biotechs and academic labs are currently exploring. Biomaterials are materials or substances designed to function in a biological environment, which may or may not be made of […] January 10, 2023 - 14 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 9 Jan 2023 The biggest private biotech investments in December 2022 The companies Apogee Therapeutics, Pulmocide and Qitan Technology bagged the biggest biotech investments in December 2022. Around the world, immunology and manufacturing players attracted the biggest funding rounds. We’ve hit 2023 and a lot of biotech fundraising took place in the final month of 2022. We’ve gathered the biggest biotech investments that went to private […] January 9, 2023 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 5 Jan 2023 Navignostics maps tumor proteomes to improve precision oncology New cancer drugs are entering the market every year, but it’s hard to know which patients they benefit the most. The Swiss firm Navignostics is making spatial maps of the tumor’s proteome to identify the right treatment for the patient and boost precision oncology approaches. A wide range of technologies is being deployed in the […] January 5, 2023 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 22 Dec 2022 10 biotech companies to watch in 2023 2022 is coming to an end. Here is a list of biotech companies from around the world that we are keeping in our sights in 2023. The year 2022 has seen a lot of uncertainty in biotech markets, resulting in tumbling or volatile stocks. A high number of biotech companies are even trading with market […] December 22, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 20 Dec 2022 Ebvallo approval ushers in off-the-shelf T-cell immunotherapies Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU approval of Atara Biotherapeutics’ Ebvallo marks the first immunotherapy based on T cells sourced from healthy donors. Since the approvals of Kymriah and Yescarta in 2017, CAR-T immunotherapies have changed the way we treat rare forms of blood cancer. In […] December 20, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 15 Dec 2022 To avoid stagnation, the EU must refine its ATMP regulation Over the decades, the EU has spearheaded the adoption of advanced therapy medicinal products (ATMPs) such as cell and gene therapies. However, changes are needed to ATMP regulations to keep Europe competitive with the rest of the world. The EU has a rich resource base in terms of biotech innovation. Over the last decades, this […] December 15, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 5 Dec 2022 The biggest private biotech investments in November 2022 The companies Emalex Biosciences, Osler Diagnostics and TauRx Pharmaceuticals bagged the biggest biotech investments in November 2022. Around the world, oncology and cell therapy players attracted the biggest funding rounds. We’re approaching the December holidays and, while lower than in 2021, biotech stocks overall have stayed relatively flat in the last few months. In the […] December 5, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 3 Nov 2022 What’s on the horizon for gene editing-based therapies? Gene editing has come far in the past decade. However, the field is still finding its feet regarding challenges such as drug delivery, regulation and competition with first-generation gene therapies. Gene editing is a sizzling hot topic in the biotech industry, powered by advances in genetic tools such as CRISPR, TALENs and zinc-finger nucleases. Gene […] November 3, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 1 Nov 2022 The biggest private biotech investments in October 2022 The companies Tempus Labs, Oculis and VectorBuilder Biotechnology bagged the biggest biotech investments in October 2022. Oncology and biomanufacturing research attracted the biggest funding rounds. We’re heading for the beginning of winter in the Northern Hemisphere, and biotech fundraising is still ticking away despite adverse market conditions. We’ve gathered the biggest biotech investments that went […] November 1, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 20 Oct 2022 Opportunities and challenges for cell and gene therapy investments Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could be an opportunity for the strongest companies and investors to shine. After several years of record-breaking investments, funding is hard to come by in the gene and cell therapy space. Part of this trend relates […] October 20, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email